865451-01-0

Basic information

• Product Name: 1-(5-chloro-4-fluoro-2-hydroxyphenyl)ethan-1-one
• Synonyms: 1-(5-chloro-4-fluoro-2-hydroxyphenyl)ethan-1-one
• CAS NO: 865451-01-0
• Molecular Weight: 188.586
• Mol File: 865451-01-0.mol
• Article Data: 15

Chemical Properties

• CAS DataBase Reference: 1-(5-chloro-4-fluoro-2-hydroxyphenyl)ethan-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(5-chloro-4-fluoro-2-hydroxyphenyl)ethan-1-one(865451-01-0)
• EPA Substance Registry System: 1-(5-chloro-4-fluoro-2-hydroxyphenyl)ethan-1-one(865451-01-0)

Safety Data

• Hazardous Substances Data: 865451-01-0(Hazardous Substances Data)

Usage

Preparation

Obtained by reaction of acetyl chloride with 4-chloro-3- fluorophenol in the presence of aluminium chloride in toluene, first at 40° for 1 h, then at 80° for 3 h (61%).

Upstream product

• 1481-27-2 4-Fluoro-2-hydroxyacetophenone 
• 348-60-7 4-chloro-3-fluorophenol 
• 75-36-5 acetyl chloride 

Downstream Products

• 937817-43-1 (2-acetyl-4-chloro-5-fluorophenoxy)acetic acid ethyl ester 
• 1426698-88-5 (4R)-4-{3-[(1S)-1-{4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl}ethyl]-5-chloro-2-ethoxy-6-fluorophenyl}pyrrolidin-2-one 
• 1426698-88-5 (4R)-4-{3-[(1R)-1-{4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl}ethyl]-5-chloro-2-ethoxy-6-fluorophenyl}pyrrolidin-2-one 
• 1426698-88-5 (4S)-4-{3-[(1S)-1-{4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl}ethyl]-5-chloro-2-ethoxy-6-fluorophenyl}pyrrolidin-2-one 
• 1426698-88-5 (4S)-4-{3-[(1R)-1-{4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl}ethyl]-5-chloro-2-ethoxy-6-fluorophenyl}pyrrolidin-2-one 

Relevant articles and documents

METHODS OF CANCER TREATMENT USING ANTI-OX40 ANTIBODIES IN COMBINATION WITH PI3 KINASE DELTA INHIBITORS

Provided are methods of treating cancer with non-competitive, agonist anti-OX40 antibodies and antigen-binding fragments thereof that bind to human OX40 (ACT35, CD134, or TNFRSF4), in combination with a PI3K (phosphatidylinositol-4, 5-bisphosphate 3-kinas

INCB050465 (Parsaclisib), a Novel Next-Generation Inhibitor of Phosphoinositide 3-Kinase Delta (PI3Kδ)

A medicinal chemistry effort focused on identifying a structurally diverse candidate for phosphoinositide 3-kinase delta (PI3Kδ) led to the discovery of clinical candidate INCB050465 (20, parsaclisib). The unique structure of 20 contains a pyrazolopyrimidine hinge-binder in place of a purine motif that is present in other PI3Kδinhibitors, such as idelalisib (1), duvelisib (2), and INCB040093 (3, dezapelisib). Parsaclisib (20) is a potent and highly selective inhibitor of PI3Kδwith drug-like ADME properties that exhibited an excellent in vivo profile as demonstrated through pharmacokinetic studies in rats, dogs, and monkeys and through pharmacodynamic and efficacy studies in a mouse Pfeiffer xenograft model.

IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS

Disclosed is a compound of Formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of treating PI3Kδ related disorders or diseases by using the c